Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper - NETs

1913O - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Date

20 Sep 2020

Session

Proffered Paper - NETs

Presenters

Mimi Hu

Citation

Annals of Oncology (2020) 31 (suppl_4): S1026-S1033. 10.1016/annonc/annonc293

Authors

M. Hu1, V. Subbiah2, L.J. Wirth3, M. Schuler4, A.S. Mansfield5, M.S. Brose6, G. Curigliano7, S. Leboulleux8, V.W. Zhu9, B. Keam10, I. Matos11, C. Lin12, D. Adkins13, C.S. Baik14, G. Lopes15, Y. Godbert16, D. Sarker17, H. Zhang18, C. Turner18, M. Taylor19

Author affiliations

  • 1 Endocrine Neoplasia And Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 2 Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 3 Department Of Medicine, Massachusetts General Hospital, Harvard Medical School, 2114 - Boston/US
  • 4 West German Cancer Center, University Duisburg-Essen & German Cancer Consortium (DKTK), Partner Site University Hospital Essen, 45122 - Essen/DE
  • 5 Division Of Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 6 Department Of Otorhinolaryngology: Head And Neck Surgery, Abramson Cancer Center, University of Pennsylvania, 19104 - Philadelphia/US
  • 7 Departments Of Oncology And Hemato-oncology, European Institute of Oncology, IRCCS and University of Milano, 20141 - Milan/IT
  • 8 Medecine Nuclear And Endocrine Oncology, Gustave Roussy, 94805 - Villejuif/FR
  • 9 Department Of Medicine, University of California - Irvine, Orange/US
  • 10 Department Of Internal Medicine, Seoul National University Hospital, Seoul/KR
  • 11 Early Drug Development Unit, Vall d'Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 12 Department Of Oncology, National Taiwan University Hospital, 10002 - Taipei City/TW
  • 13 Division Of Oncology, Washington University School of Medicine, St Louis/US
  • 14 Thoracic, Head And Neck Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 98109 - Seattle/US
  • 15 Sylvester Comprehensive Cancer Center, University of Miami, 33146 - Miami/US
  • 16 Nuclear Medicine, Bergonié Institute Cancer Center, 33076 - Bordeaux/FR
  • 17 Department Of Medical Oncology, Guy's Hospital, King's College London, London/GB
  • 18 -, Blueprint Medicines Corporation, Cambridge/US
  • 19 Earle A. Chiles Research Institute, Providence Cancer Institute, 97210 - Portland/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1913O

Background

Pralsetinib is a highly potent, selective RET inhibitor targeting oncogenic RET alterations. We provide the registrational data for pts with RET+ MTC from the ARROW study.

Methods

ARROW (75 sites in 11 countries; NCT03037385) consists of a phase I dose escalation to establish the recommended phase II dose (400 mg once daily [QD] orally), and phase II expansion cohorts defined by tumour type and/or RET alteration. Primary phase II objectives are overall response rate (ORR; blinded independent central review per RECIST v1.1) and safety. We report efficacy for response-evaluable pts (REP) with RET+ MTC and safety for all pts who initiated pralsetinib 400 mg QD, both as of data cut-off date 13 Feb 2020.

Results

In 79 REP with RET+ MTC (mutation: 61% M918T, 28% C634X, 4% V804X, 8% other), ORR was 65% (95% CI, 53–75; n=51/79, 5% complete response [CR]; 59% partial response [PR; 1 pending confirmation]). ORR for pts with prior cabozantinib and/or vandetanib (C/V) was 60% (95% CI, 46–74; n=32/53; 2% CR; 58% PR [1 pending]) and in treatment-naïve pts ORR was 74% (95% CI, 49–91; n=14/19; 5% CR; 68% PR; all confirmed). Disease control rate was 97% (95% CI, 91–100); 99% (78/79) of pts experienced tumour shrinkage. Median progression-free survival (PFS) and duration of response (DOR) were not reached. In pts previously treated with C/V 18-mo PFS was 71% (95% CI, 58–85), and 18-mo DOR was 90% (95% CI, 77–100). In treatment-naïve pts, 18-mo PFS was 85% (95% CI, 65–100) and 86% (12/14) of responses were ongoing at data cut-off (up to 15 mo). Responses occurred regardless of RET genotypes (somatic or germline), including 5 of 6 pts with V804X gatekeeper mutation. In the safety population (n=438), treatment-related adverse events (TRAEs) were primarily grade 1–2; most common any-grade TRAEs were increased aspartate aminotransferase (34%), anaemia (24%), increased alanine aminotransferase (23%), constipation (23%) and hypertension (22%). 4% of pts discontinued due to TRAEs.

Conclusions

Pralsetinib demonstrated potent and durable clinical activity in RET+ MTC regardless of prior treatment with approved multikinase inhibitors or RET-mutation and was well tolerated.

Clinical trial identification

NCT03037385.

Editorial acknowledgement

Medical writing support was provided by Miriam Cohen, PhD, and editorial support was provided by Sinead Stewart, all of Paragon, Knutsford, UK, supported by Blueprint Medicines Corporation, Cambridge, MA according to Good Publication Practice guidelines.

Legal entity responsible for the study

Blueprint Medicines Corporation.

Funding

Blueprint Medicines Corporation.

Disclosure

M. Hu: Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Eli Lilly & Co; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Veracyte. V. Subbiah: Research grant/Funding (self): Roche/Genentech; Research grant/Funding (self): Novartis; Research grant/Funding (self): Bayer; Research grant/Funding (self): GSK; Research grant/Funding (self): Nanocarrier; Research grant/Funding (self): Vegenics; Research grant/Funding (self): Celgene; Research grant/Funding (self): Northwest Biotherapeutics; Research grant/Funding (self): Berghealth; Research grant/Funding (self): Incyte; Research grant/Funding (self): Fujifilm; Research grant/Funding (self): PharmaMar; Research grant/Funding (self): D3; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Multivir; Research grant/Funding (self): Amgen; Research grant/Funding (self): AbbVie; Research grant/Funding (self): Alfa-sigma; Research grant/Funding (self): Agensys; Research grant/Funding (self): Boston Biomedical; Research grant/Funding (self): Idera Pharma; Research grant/Funding (self): Inhibrx; Research grant/Funding (self): Exelixis; Research grant/Funding (self): Blueprint Medicines Corporation; Research grant/Funding (self): Loxo Oncology; Research grant/Funding (self): MedImmune; Research grant/Funding (self): Altum; Research grant/Funding (self): Dragonfly Therapeutics; Research grant/Funding (self): Takeda; Research grant/Funding (self): National Comprehensive Cancer Network. L.J. Wirth: Advisory/Consultancy: Bayer; Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Cue Biopharma; Advisory/Consultancy: Eisai; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Genentech; Advisory/Consultancy: Lilly; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Merck; Advisory/Consultancy: Rakuten Medical. M. Schuler: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: Novartis; Advisory/Consultancy: Roche; Advisory/Consultancy: Takeda; Advisory/Consultancy: MorphoSys. A.S. Mansfield: Honoraria (institution): AbbVie; Honoraria (institution): AstraZeneca; Honoraria (institution): BMS; Honoraria (institution): Roche/Genentech; Travel/Accommodation/Expenses: Novartis; Research grant/Funding (institution): Verily Research; Non-remunerated activity/ies: Mesothelioma Applied Research Foundation. M.S. Brose: Honoraria (self), Research grant/Funding (institution): Exelixis; Advisory/Consultancy, Research grant/Funding (institution): Blueprint Medicines Corporation; Advisory/Consultancy, Research grant/Funding (institution): Lilly; Honoraria (self), Advisory/Consultancy: Bayer; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self): Raffo; Advisory/Consultancy: Loxo. G. Curigliano: Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics; Speaker Bureau/Expert testimony: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy, Speaker Bureau/Expert testimony: NanoString; Advisory/Consultancy, Speaker Bureau/Expert testimony: Samsung; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celltrion; Non-remunerated activity/ies: Ellipsis; Speaker Bureau/Expert testimony: BMS; Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan. S. Leboulleux: Advisory/Consultancy: Lilly; Advisory/Consultancy: Bayer; Speaker Bureau/Expert testimony: Eisai. V.W. Zhu: Honoraria (self): AstraZeneca; Honoraria (self): Roche/Foundation Medicine; Honoraria (self): Roche/Genentech; Honoraria (self): Takeda; Shareholder/Stockholder/Stock options: TP Therapeutics. B. Keam: Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): MSD Oncology; Advisory/Consultancy: ABL Bio; Advisory/Consultancy: Genexine; Advisory/Consultancy: Cellid; Advisory/Consultancy: Ono Pharmaceutical. I. Matos: Research grant/Funding (self): Roche. C-C. Lin: Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy: Novartis; Advisory/Consultancy: Takeda; Honoraria (self): BMS; Honoraria (self): Roche; Travel/Accommodation/Expenses: BeiGene; Travel/Accommodation/Expenses: Eli Lilly. D. Adkins: Advisory/Consultancy: Lilly; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Celgene; Advisory/Consultancy: Merck; Advisory/Consultancy: CUE; Advisory/Consultancy: Aduro; Advisory/Consultancy: KURA; Advisory/Consultancy: Oncolys; Advisory/Consultancy: Enzychyme; Advisory/Consultancy: Matrix; Advisory/Consultancy: Celldex. C.S. Baik: Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): Celgene; Research grant/Funding (self): Novartis; Research grant/Funding (self): MedImmune; Research grant/Funding (self): SWOG; Research grant/Funding (self): Genentech; Research grant/Funding (self): Loxo Oncology; Research grant/Funding (self): Pfizer; Research grant/Funding (self): Spectrum Pharmaceuticals; Research grant/Funding (self): Blueprint Medicines Corporation; Research grant/Funding (self): Daiichi Sankyo; Research grant/Funding (self): Rain Therapeutics; Research grant/Funding (self): AbbVie; Research grant/Funding (self): TP Therapeutics; Research grant/Funding (self): Lilly Oncology. G. Lopes: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Honoraria (self), Travel/Accommodation/Expenses: Boehringer Ingelheim; Travel/Accommodation/Expenses: E R Squibb Sons; Research grant/Funding (institution), Travel/Accommodation/Expenses: Janssen; Research grant/Funding (institution): MSD; Research grant/Funding (institution): EMD Serono; Research grant/Funding (institution): Blueprint Medicines Corporation; Research grant/Funding (institution): Tesaro; Research grant/Funding (institution): Bavarian Nordic; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (institution): Adaptimmune; Research grant/Funding (institution): BMS; Research grant/Funding (institution): GSK; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Rgenix; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Lilly. D. Sarker: Honoraria (self): Pfizer; Honoraria (self): Bayer; Advisory/Consultancy: Ipsen; Honoraria (self): Novartis; Advisory/Consultancy: Eisai; Advisory/Consultancy: Surface Oncology; Advisory/Consultancy: MSD Oncology. H. Zhang, C. Turner: Shareholder/Stockholder/Stock options, Full/Part-time employment: Blueprint Medicines Corporation. M. Taylor: Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy: Array BioPharma; Advisory/Consultancy: Loxo Oncology; Advisory/Consultancy: Bayer; Advisory/Consultancy: ArQule; Advisory/Consultancy: Blueprint Medicines Corporation; Advisory/Consultancy: Novartis; Advisory/Consultancy: Sanofi/Genzyme; Speaker Bureau/Expert testimony: Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings